Trials / Completed
CompletedNCT03931447
A Safety and Tolerability Study of JNJ-72537634 in Healthy Participants
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Day Dose Study To Assess The Safety And Tolerability Of JNJ-72537634 In Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to assess the safety and tolerability of JNJ-72537634 compared with placebo in healthy participants after administration of single and multiple day doses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | JNJ-72537634 | Participants in Cohort 1 and 3 will receive Dose 1 and participants in Cohort 2 and 4 will receive Dose 2 of JNJ-72537634 as oral capsule. |
| BIOLOGICAL | Placebo | Participants will receive matching placebo as oral capsule in all cohorts. |
Timeline
- Start date
- 2019-04-30
- Primary completion
- 2020-02-10
- Completion
- 2020-02-10
- First posted
- 2019-04-30
- Last updated
- 2025-05-23
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT03931447. Inclusion in this directory is not an endorsement.